Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Glioblastoma and all gliomas – Tafinlar plus Mekinist, a durable benefit

Background – Glioblastoma and BRAF

BRAFV600E mutations are rarely encountered in adult glioblastoma with an incidence ranging from less than 1% to 8%. But young adults, i.e. 17 to 35 years, seem to have higher mutation rates of up to 15%.

BRAF V600E mutations should be considered for routine testing as they are part of the many factors that drive the development of many cancers.

Tafinlar is a drug which targets BRAFV600E mutations and therefore can cause the tumor to stop growing and kill its cells.

Mekinist is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity. It inhibits MEK1 and MEK2 which are components in the inner part of the tumor cell that also contribute to its growth and proliferation.

The combination of these two drugs is approved for treating Melanoma patients.

And now a durable clinical benefit was seen from this combination in treating patients with BRAF V600E mutant low- and high-grade glioma, such as Glioblastoma. It was a phase 2 study by the name ” ROAR study”.

About the ROAR clinical trial

ROAR was a study of Tafinlar and Mekinist in patients with BRAF V600E mutation–positive rare cancers.

37 patients with glioma were enrolled and included in the primary analysis.

Only patients with advanced disease and no available standard treatment options were eligible for enrollment to the study.

Patients received Tafinlar 150 mg twice daily and Mekinist 2 mg once daily.

Results of the High Grade Glioma Cohort, e.g. Glioblastoma

  • 24% of patients had their tumor decrease in volume
  • 7% of patients had their tumors vanished from the MRI!
  • The median duration of response was 36.9 months (over 3 years)
  • At 2 years, 68.8% of patients were still responding to the treatment
  • The median survival was 17.6 months which is more than the standard of care. Mind this is “median” – meaning 50% lived longer than 17.6 months and 50% less.

Results of the Law Grade Glioma Cohort

  • 69.0% of patients had their tumor decrease in volume
  • 8% of patients had their tumors vanished from the MRI!
  • The median duration of response was not reached
  • At 2 years, 76.2% of patients were still responding to the treatment
  • The median survival was still not reached at the time of the analysis

Side Effects

The hardest side effects were fatigue (9% of patients), neutrophil count decreased (9%), headache (5%) and neutropenia (5%).

Some patients needed dose reduction and some stopped the treatment due to the side effects.

Contact us so we can help you to actually get the most advanced treatments

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

For further reading>>

More information about Glioblastoma>>

Gliomas - Mekinist plus Tafinlar
Gliomas – Mekinist plus Tafinlar

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics